← Back to all signals
RESEARCH PAPER ANALYSIS

Quantitative ultrasound radiofrequency analysis for monitoring Parkinson's disease.

Quantitative ultrasound radiofrequency Nakagami imaging detected increased muscle scattering (higher m parameter) across multiple muscles in Parkinson's patients versus controls, with the gastrocnemius medialis m strongly correlating with disease severity and good diagnostic performance in a small…

PMID41956318
JournalNeuroscience
Publication Date2026-04-07
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Quantitative ultrasound radiofrequency Nakagami imaging detected increased muscle scattering (higher m parameter) across multiple muscles in Parkinson's patients versus controls, with the gastrocnemius medialis m strongly correlating with disease severity and good diagnostic performance in a small…

WHY IT MATTERS

Research significance

This noninvasive, rapid, low-cost imaging biomarker could provide an objective tool for diagnosis and longitudinal monitoring to improve patient stratification and endpoint sensitivity in clinical studies, although findings are preliminary given the small sample and lack of mechanistic linkage to…

ABSTRACT

Source abstract

Current clinical assessments of Parkinson's disease rely largely on functional scales, which lack sensitivity to subtle muscle alterations. Therefore, developing objective and quantitative tools to support both diagnosis and disease monitoring is needed. Quantitative ultrasound radiofrequency imaging, particularly through Nakagami analysis, offers a non-invasive means of characterizing tissue scattering properties that may reflect Parkinson's disease - related effects. This study aimed to assess the feasibility of quantitative ultrasound radiofrequency imaging in identifying muscle alterations and disease severity in individuals with Parkinson's disease. Seventeen individuals with Parkinson's disease and 14 healthy controls participated in this study. Patients with Parkinson's disease were divided into early and late stages based on the Hoehn and Yahr scale. Quantitative ultrasound radiofrequency data were collected on each individual's gastrocnemius medialis, tibialis anterior, triceps brachii, and biceps brachii, and analyzed to estimate the Nakagami m parameter. The Nakagami m parameter was significantly higher in patients with Parkinson's disease compared to healthy controls across all muscles, with the largest differences in the gastrocnemius medialis. The Nakagami m parameter in this muscle was strongly associated with disease severity and showed excellent diagnostic performance. No significant asymmetry was observed between the most and least affected limb. These data indicate that quantitative ultrasound radiofrequency Nakagami imaging can detect muscle microstructural alterations associated with Parkinson's disease and is associated with disease severity. This approach shows strong potential as a rapid, low-cost, and quantitative biomarker for the diagnosis and longitudinal monitoring of Parkinson's disease.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic